
Neuroendocrine tumors (NETs) are tumors that arise from cells of the endocrine and nervous systems. More than ten years of published clinical data and personal
experience using PRRT-based targeted therapy of neuroendocrine tumors
supports the effectiveness of this novel treatment approach and the
ability to minimize and manage potential toxic side effects.
A
comprehensive review of somatostatin analog peptide receptor
radionuclide therapy (PRRT) is published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
In the article "Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuendocrine Tumors: A Decade od Experience," Murali Kesavan and J. Harvey Turner, The University of Western Australia (Crawley, Australia), state that PRRT has revolutionized the management of patients with neuroendocrine tumors, improving tumor response rates and patients' progression-free survival. However, the associated toxicity to blood cells - with the potential to cause thrombocytopenia and neutropenia and, in the long term, myelodysplastic syndrome and acute leukemia - remains a risk and has limited the use of PRRT.
"This is an important discussion of the efficacy and toxicity issues relating to the use of PRRT, as the therapy becomes more widely available for the treatment of gastroenteropancreatic neuroendocrine tumors with radiolabeled somatostatin analogs," says Co-Editor-in-Chief Donald J. Buchsbaum, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham.
Source: Eurekalert
Advertisement
|